Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, November 2nd, MarketBeat.com reports. They presently have a $17.00 price objective on the biotechnology company’s stock, down from their previous price objective of $18.00. HC Wainwright’s price target would suggest a potential upside of 321.84% from the company’s previous close.
Several other research firms have also recently weighed in on CNAT. Zacks Investment Research cut shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Stifel Nicolaus restated a “buy” rating and set a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Finally, Seaport Global Securities reiterated a “buy” rating and issued a $16.00 target price on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $16.00.
Conatus Pharmaceuticals (CNAT) traded down $0.05 during trading hours on Thursday, reaching $4.03. 255,294 shares of the company’s stock traded hands, compared to its average volume of 617,649. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.41. Conatus Pharmaceuticals has a 52-week low of $1.73 and a 52-week high of $9.40.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The company had revenue of $9.57 million for the quarter, compared to analysts’ expectations of $16.06 million. During the same quarter in the previous year, the business earned ($0.31) EPS. equities analysts forecast that Conatus Pharmaceuticals will post -0.65 earnings per share for the current year.
WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/conatus-pharmaceuticals-cnat-buy-rating-reiterated-at-hc-wainwright/1750882.html.
Several hedge funds and other institutional investors have recently modified their holdings of CNAT. Voya Investment Management LLC bought a new position in shares of Conatus Pharmaceuticals in the second quarter worth approximately $101,000. Wells Fargo & Company MN raised its holdings in shares of Conatus Pharmaceuticals by 3,098.0% during the third quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 18,588 shares during the last quarter. Bank of Montreal Can purchased a new stake in Conatus Pharmaceuticals during the second quarter valued at approximately $109,000. FNY Partners Fund LP increased its holdings in Conatus Pharmaceuticals by 98.0% during the second quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 9,800 shares during the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in Conatus Pharmaceuticals during the second quarter valued at approximately $115,000. Hedge funds and other institutional investors own 34.06% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.